|
|
 |
|
Viewing report
|
|
|
|
Women's Health Market Strategies - Opportunities remain in this overlooked therapy area
Datamonitor, Oct 2011, Pages: 135
Investment in women’s health has suffered in recent years as the pharmaceutical industry moves towards specialist care and biological therapies. The traditional view is that women’s health bears several barriers to entry that limit return and deter investment, such as high market competition, stigma, and regulatory restrictions. Nevertheless, opportunities remain in this overlooked therapy area.
Features and benefits
- Analyze the leading players involved in women’s health, including SWOT analyses and franchise revenue projections to 2016.
- Clinical and commercial attractiveness assessment of key women’s health indications to identify the best markets to enter.
- Identify key marketing and corporate strategies used by current women’s health companies and understand the impact of key recent licensing deals.
- PESTL analysis provides further exploration of the major drivers and resistors in the women’s health sector.
- Analysis of sales trends and FDA approvals in women’s health compared to other therapy areas.
Highlights
- In 2010, the women’s health market generated $12bn sales for the top 50 drug companies, accounting for 2.1% of total pharmaceutical sales. Bayer-Schering is the leading player in the sector with sales nearing $3bn in 2010 and will continue to dominate the market. Other key players include Pfizer, Warner Chilcott, Teva, Merck KGaA, and Merck & Co.
- The decreasing interest in women’s health is due to the perceived poor return on investment compared to other sectors. There are several barriers to entry, including high stigma, poor treatment education, regulatory restrictions, and lack of scientific innovation. The perceived lower level of unmet need and high competition further deter investment
- Companies can increase the patient potential of their products by raising awareness, destigmatizing conditions, and dispelling safety concerns utilizing modern day marketing channels. Moreover, portfolios can be further optimized by expansions into non-traditional women’s health disorders and new geographies, particularly India and China.
Your key questions answered
- Which women’s health indications are the most and least commercially viable?
- What are the main challenges companies are facing in this therapy area?
- How are the leading companies in women’s health performing?
- Should companies invest in women’s health?
- How does the sector differ from other therapy areas?
|
|
|
|
